Concepts (184)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Autistic Disorder | 14 | 2020 | 43 | 2.960 |
Why?
|
| Anticonvulsants | 7 | 2025 | 8 | 1.720 |
Why?
|
| Seizures | 5 | 2025 | 14 | 1.660 |
Why?
|
| Epilepsy | 8 | 2025 | 11 | 1.330 |
Why?
|
| Diazepam | 1 | 2025 | 3 | 0.960 |
Why?
|
| Child, Preschool | 19 | 2023 | 177 | 0.930 |
Why?
|
| Child | 20 | 2023 | 336 | 0.920 |
Why?
|
| Humans | 31 | 2025 | 4931 | 0.830 |
Why?
|
| Quinidine | 1 | 2020 | 1 | 0.680 |
Why?
|
| Dopamine Antagonists | 1 | 2020 | 1 | 0.680 |
Why?
|
| Dextromethorphan | 1 | 2020 | 2 | 0.680 |
Why?
|
| Male | 23 | 2025 | 2620 | 0.610 |
Why?
|
| Blood Transfusion, Autologous | 1 | 2018 | 2 | 0.580 |
Why?
|
| Stem Cells | 1 | 2018 | 14 | 0.580 |
Why?
|
| Umbilical Cord | 1 | 2018 | 9 | 0.580 |
Why?
|
| Fetal Blood | 1 | 2018 | 41 | 0.570 |
Why?
|
| Autism Spectrum Disorder | 1 | 2018 | 23 | 0.560 |
Why?
|
| Adolescent | 11 | 2025 | 569 | 0.550 |
Why?
|
| Female | 19 | 2025 | 2964 | 0.530 |
Why?
|
| Electroencephalography | 4 | 2006 | 13 | 0.520 |
Why?
|
| Child Development Disorders, Pervasive | 3 | 2007 | 8 | 0.500 |
Why?
|
| Adult | 11 | 2025 | 1402 | 0.500 |
Why?
|
| Treatment Outcome | 9 | 2025 | 402 | 0.480 |
Why?
|
| Double-Blind Method | 5 | 2022 | 81 | 0.450 |
Why?
|
| Infant | 9 | 2023 | 132 | 0.440 |
Why?
|
| Autoimmune Diseases | 2 | 2010 | 5 | 0.400 |
Why?
|
| Young Adult | 6 | 2025 | 382 | 0.390 |
Why?
|
| Lennox Gastaut Syndrome | 2 | 2023 | 2 | 0.370 |
Why?
|
| Cannabidiol | 2 | 2023 | 3 | 0.370 |
Why?
|
| Immunotherapy | 1 | 2010 | 13 | 0.340 |
Why?
|
| Valproic Acid | 3 | 2006 | 4 | 0.330 |
Why?
|
| Cross-Over Studies | 2 | 2020 | 22 | 0.310 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2009 | 4 | 0.310 |
Why?
|
| Adrenergic alpha-Agonists | 1 | 2009 | 4 | 0.310 |
Why?
|
| Clonidine | 1 | 2009 | 3 | 0.310 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2009 | 17 | 0.310 |
Why?
|
| Databases, Factual | 1 | 2009 | 60 | 0.300 |
Why?
|
| Pyridones | 2 | 2025 | 3 | 0.290 |
Why?
|
| Polysomnography | 2 | 2006 | 2 | 0.290 |
Why?
|
| Middle Aged | 5 | 2025 | 1544 | 0.280 |
Why?
|
| Encephalitis | 1 | 2007 | 3 | 0.280 |
Why?
|
| Sleep Wake Disorders | 2 | 2004 | 14 | 0.280 |
Why?
|
| Memantine | 1 | 2007 | 1 | 0.280 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2007 | 9 | 0.270 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2007 | 34 | 0.270 |
Why?
|
| Drug Therapy, Combination | 3 | 2025 | 58 | 0.270 |
Why?
|
| Nasal Sprays | 1 | 2025 | 1 | 0.240 |
Why?
|
| Administration, Intranasal | 1 | 2025 | 4 | 0.240 |
Why?
|
| Communication Disorders | 1 | 2004 | 1 | 0.230 |
Why?
|
| Preservatives, Pharmaceutical | 1 | 2004 | 1 | 0.230 |
Why?
|
| Thimerosal | 1 | 2004 | 1 | 0.230 |
Why?
|
| Self-Injurious Behavior | 1 | 2004 | 6 | 0.230 |
Why?
|
| Anxiety Disorders | 1 | 2004 | 5 | 0.230 |
Why?
|
| Immunization | 1 | 2004 | 18 | 0.230 |
Why?
|
| Aggression | 2 | 2020 | 6 | 0.230 |
Why?
|
| Depressive Disorder | 1 | 2004 | 24 | 0.230 |
Why?
|
| Consensus | 1 | 2024 | 32 | 0.220 |
Why?
|
| Carbamates | 1 | 2004 | 1 | 0.220 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2004 | 1 | 0.220 |
Why?
|
| Phenylcarbamates | 1 | 2004 | 1 | 0.220 |
Why?
|
| Retrospective Studies | 4 | 2022 | 513 | 0.220 |
Why?
|
| Status Epilepticus | 2 | 2024 | 2 | 0.210 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2004 | 58 | 0.210 |
Why?
|
| Compassionate Use Trials | 1 | 2023 | 2 | 0.210 |
Why?
|
| Carnosine | 1 | 2002 | 1 | 0.200 |
Why?
|
| Neuroprotective Agents | 1 | 2002 | 14 | 0.200 |
Why?
|
| Brain | 5 | 2019 | 78 | 0.200 |
Why?
|
| 4-Aminopyridine | 1 | 2020 | 1 | 0.170 |
Why?
|
| Vesicle-Associated Membrane Protein 2 | 1 | 2020 | 1 | 0.170 |
Why?
|
| Mutation | 1 | 2020 | 51 | 0.170 |
Why?
|
| Irritable Mood | 1 | 2020 | 1 | 0.170 |
Why?
|
| Secretin | 1 | 2000 | 9 | 0.170 |
Why?
|
| Pilot Projects | 1 | 2020 | 53 | 0.170 |
Why?
|
| Neurodevelopmental Disorders | 1 | 2019 | 1 | 0.160 |
Why?
|
| Receptors, AMPA | 1 | 2019 | 3 | 0.160 |
Why?
|
| Intellectual Disability | 1 | 2019 | 6 | 0.160 |
Why?
|
| Drug Resistant Epilepsy | 1 | 2019 | 1 | 0.160 |
Why?
|
| Epilepsies, Myoclonic | 1 | 2019 | 1 | 0.160 |
Why?
|
| Primates | 1 | 2018 | 2 | 0.150 |
Why?
|
| Arginine Vasopressin | 1 | 2018 | 46 | 0.150 |
Why?
|
| Landau-Kleffner Syndrome | 3 | 2005 | 3 | 0.140 |
Why?
|
| Aged | 3 | 2025 | 1188 | 0.140 |
Why?
|
| Infant, Newborn | 2 | 2009 | 121 | 0.130 |
Why?
|
| Autoantibodies | 3 | 2005 | 6 | 0.130 |
Why?
|
| Animals | 4 | 2018 | 1369 | 0.120 |
Why?
|
| Risk Factors | 2 | 2010 | 593 | 0.120 |
Why?
|
| Psychiatric Status Rating Scales | 2 | 2007 | 12 | 0.120 |
Why?
|
| Monitoring, Ambulatory | 2 | 2006 | 5 | 0.120 |
Why?
|
| Immunoglobulin G | 4 | 2005 | 10 | 0.110 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2004 | 44 | 0.110 |
Why?
|
| Phenytoin | 1 | 1994 | 1 | 0.110 |
Why?
|
| Brain Diseases | 1 | 1994 | 2 | 0.110 |
Why?
|
| Nitriles | 2 | 2025 | 11 | 0.110 |
Why?
|
| Follow-Up Studies | 2 | 2007 | 202 | 0.100 |
Why?
|
| Biomarkers | 2 | 2018 | 160 | 0.100 |
Why?
|
| Social Behavior | 2 | 2018 | 12 | 0.090 |
Why?
|
| Meningitis | 1 | 1989 | 2 | 0.080 |
Why?
|
| Ibuprofen | 1 | 1989 | 3 | 0.080 |
Why?
|
| Injections, Intravenous | 2 | 2000 | 13 | 0.080 |
Why?
|
| Central Nervous System | 1 | 2007 | 6 | 0.070 |
Why?
|
| Early Diagnosis | 1 | 2007 | 20 | 0.070 |
Why?
|
| Aged, 80 and over | 1 | 2009 | 407 | 0.070 |
Why?
|
| Severity of Illness Index | 1 | 2007 | 76 | 0.070 |
Why?
|
| Nervous System | 1 | 2005 | 2 | 0.060 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2005 | 2 | 0.060 |
Why?
|
| Nervous System Diseases | 2 | 1999 | 5 | 0.060 |
Why?
|
| Measles-Mumps-Rubella Vaccine | 1 | 2004 | 1 | 0.060 |
Why?
|
| Vitamins | 1 | 2004 | 12 | 0.060 |
Why?
|
| Complementary Therapies | 1 | 2004 | 9 | 0.060 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2004 | 10 | 0.060 |
Why?
|
| Outpatients | 1 | 2024 | 8 | 0.060 |
Why?
|
| Delphi Technique | 1 | 2024 | 11 | 0.060 |
Why?
|
| Reference Values | 1 | 2004 | 41 | 0.060 |
Why?
|
| Rivastigmine | 1 | 2004 | 1 | 0.060 |
Why?
|
| Pattern Recognition, Visual | 1 | 2004 | 1 | 0.060 |
Why?
|
| Vocabulary | 1 | 2004 | 2 | 0.060 |
Why?
|
| Language Development Disorders | 1 | 2004 | 2 | 0.060 |
Why?
|
| Acetylcholine | 1 | 2004 | 2 | 0.060 |
Why?
|
| Personality Assessment | 1 | 2004 | 6 | 0.060 |
Why?
|
| Neuropsychological Tests | 1 | 2004 | 9 | 0.060 |
Why?
|
| Cognition Disorders | 1 | 2004 | 14 | 0.060 |
Why?
|
| Siblings | 1 | 2004 | 6 | 0.050 |
Why?
|
| Disease Progression | 1 | 2024 | 137 | 0.050 |
Why?
|
| Patient Safety | 1 | 2023 | 8 | 0.050 |
Why?
|
| Fucose | 1 | 1983 | 1 | 0.050 |
Why?
|
| Myelin Sheath | 1 | 1983 | 1 | 0.050 |
Why?
|
| Sciatic Nerve | 1 | 1983 | 1 | 0.050 |
Why?
|
| Leucine | 1 | 1983 | 2 | 0.050 |
Why?
|
| Diabetic Neuropathies | 1 | 1983 | 3 | 0.050 |
Why?
|
| Myelin Proteins | 1 | 1983 | 4 | 0.050 |
Why?
|
| Triazoles | 1 | 2023 | 12 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2019 | 224 | 0.050 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 1983 | 21 | 0.050 |
Why?
|
| Exocytosis | 1 | 2020 | 1 | 0.040 |
Why?
|
| Synaptic Vesicles | 1 | 2020 | 1 | 0.040 |
Why?
|
| Synaptic Transmission | 1 | 2020 | 4 | 0.040 |
Why?
|
| Electrophysiology | 1 | 2020 | 7 | 0.040 |
Why?
|
| Metronidazole | 1 | 2000 | 2 | 0.040 |
Why?
|
| Crohn Disease | 1 | 2000 | 3 | 0.040 |
Why?
|
| Anti-Infective Agents | 1 | 2000 | 5 | 0.040 |
Why?
|
| Magnetoencephalography | 1 | 1999 | 1 | 0.040 |
Why?
|
| Loss of Function Mutation | 1 | 2019 | 1 | 0.040 |
Why?
|
| Heterozygote | 1 | 2019 | 3 | 0.040 |
Why?
|
| Mental Disorders | 1 | 2000 | 43 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2019 | 41 | 0.040 |
Why?
|
| Diarrhea | 1 | 2019 | 8 | 0.040 |
Why?
|
| Macaca mulatta | 1 | 2018 | 8 | 0.040 |
Why?
|
| Mice | 2 | 1994 | 555 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2018 | 162 | 0.030 |
Why?
|
| Electroshock | 1 | 1994 | 1 | 0.030 |
Why?
|
| Drug Synergism | 1 | 1994 | 22 | 0.030 |
Why?
|
| Drug Interactions | 1 | 1994 | 26 | 0.030 |
Why?
|
| Myoclonus | 1 | 1993 | 1 | 0.030 |
Why?
|
| Ocular Motility Disorders | 1 | 1993 | 1 | 0.030 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 1993 | 23 | 0.030 |
Why?
|
| Antibodies, Antinuclear | 2 | 2005 | 2 | 0.030 |
Why?
|
| Immunoglobulin M | 2 | 2005 | 2 | 0.030 |
Why?
|
| Cerebral Cortex | 2 | 2005 | 12 | 0.030 |
Why?
|
| Immunohistochemistry | 2 | 2005 | 98 | 0.020 |
Why?
|
| Penicillin G | 1 | 1989 | 1 | 0.020 |
Why?
|
| Spinal Nerve Roots | 1 | 1989 | 1 | 0.020 |
Why?
|
| Cerebrospinal Fluid | 1 | 1989 | 2 | 0.020 |
Why?
|
| Arthritis, Infectious | 1 | 1988 | 2 | 0.020 |
Why?
|
| Mycoses | 1 | 1988 | 3 | 0.020 |
Why?
|
| Myelin Basic Protein | 1 | 2005 | 2 | 0.020 |
Why?
|
| Umbilical Veins | 1 | 2005 | 2 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2005 | 24 | 0.020 |
Why?
|
| Histones | 1 | 2005 | 10 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2005 | 13 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2005 | 164 | 0.010 |
Why?
|
| Carbon Radioisotopes | 1 | 1983 | 2 | 0.010 |
Why?
|
| Tritium | 1 | 1983 | 3 | 0.010 |
Why?
|
| Mice, Mutant Strains | 1 | 1983 | 6 | 0.010 |
Why?
|
| Sleep | 1 | 1999 | 11 | 0.010 |
Why?
|
| Temporal Lobe | 1 | 1999 | 4 | 0.010 |
Why?
|
| Radioimmunoassay | 1 | 1993 | 25 | 0.010 |
Why?
|
| Drug Tolerance | 1 | 1993 | 25 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 1993 | 23 | 0.010 |
Why?
|
| Acremonium | 1 | 1988 | 1 | 0.000 |
Why?
|
| Knee Joint | 1 | 1988 | 1 | 0.000 |
Why?
|
| Synovial Fluid | 1 | 1988 | 1 | 0.000 |
Why?
|
| Knee Injuries | 1 | 1988 | 4 | 0.000 |
Why?
|
| Wounds, Penetrating | 1 | 1988 | 8 | 0.000 |
Why?
|
| Acute Disease | 1 | 1988 | 23 | 0.000 |
Why?
|